RT Journal Article
SR Electronic
T1 The impact of COVID-19 pandemic on the provision of ambulatory care for patients with chronic neurological diseases in Japan: evaluation of an administrative claims database
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.10.21256951
DO 10.1101/2021.05.10.21256951
A1 Sato, Kenichiro
A1 Mano, Tatsuo
A1 Niimi, Yoshiki
A1 Iwata, Atsushi
A1 Toda, Tatsushi
A1 Iwatsubo, Takeshi
YR 2021
UL http://medrxiv.org/content/early/2021/05/10/2021.05.10.21256951.abstract
AB Background The COVID-19 pandemic has affected not only the emergency medical system, but also patients’ regular ambulatory care. The number of patients visiting outpatient internal medicine clinics decreased during March–April 2020 compared to 2019. Moreover, the ban on telephone re-examination for outpatient clinics in lieu of ambulatory care for chronic diseases has been lifted since March 2020. In this context, we investigate the impact of the COVID-19 pandemic on ambulatory care at Japanese outpatient clinics for patients with chronic neurological diseases during the first half of 2020.Methods We collected data from the administrative claims database by DeSC Healthcare. Serial changes in the frequency of subsequent outpatient visits to clinics or hospitals (excluding large hospitals with beds >200) for chronic ambulatory care of epilepsy, migraine, Parkinson’s disease (PD), and Alzheimer’s disease were measured. We also evaluated the utilization rate of telephone re-examination at outpatient clinics.Results Since April 2020, the monthly count of outpatient clinic visits for epilepsy or PD decreased slightly but significantly. The use of telephone re-examination was facility-dependent, and it was used in less than 5% of all outpatient clinic visits for the examined neurological diseases in May 2020. The utilization rate of telephone re-examination was not associated with age or the neurological diseases of interest.Conclusion The impact of the COVID-19 pandemic on ambulatory care for several chronic neurological diseases may have been relatively limited, in terms of the frequency or type of outpatient visit, during the first half of 2020 in Japan.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Japan Agency for Medical Research and Development grants JP17DK0207028, JP19DK0207048, 19dk0207048h0001, and 16dk0207028h0001, and by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 20J11009.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This was approved by the University of Tokyo Graduate School of Medicine Institutional Ethics Committee (ID: 11628-(3)).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study was obtained from DeSC database by application to DeSC Healthcare, Inc.